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ORIGINAL ARTICLE
Effects of the mu-opioid receptor antagonist GSK1521498 on
hedonic and consummatory eating behaviour: a proof of
mechanism study in binge-eating obese subjects
H Ziauddeen1,2,3,4,11,12, SR Chamberlain1,2,4,11,12, PJ Nathan1,2,12, A Koch1, K Maltby1, M Bush5, WX Tao6, A Napolitano1, AL Skeggs1,
AC Brooke1, L Cheke7, NS Clayton7, I Sadaf Farooqi3, S O’Rahilly3, D Waterworth8, K Song8, L Hosking9, DB Richards1,10, PC Fletcher2,4
and ET Bullmore1,2,4,12
The opioid system is implicated in the hedonic and motivational processing of food, and in binge eating, a behaviour strongly
linked to obesity. The aim of this study was to evaluate the effects of 4 weeks of treatment with the mu-opioid receptor antagonist
GSK1521498 on eating behaviour in binge-eating obese subjects. Adults with body mass indexX30 kgm 2 and binge eating scale
scores X19 received 1-week single-blind placebo run-in, and were then randomized to 28 days with either 2mgday 1
GSK1521498, 5mgday 1 GSK1521498 or placebo (N¼ 21 per arm) in a double-blind parallel group design. The outcome measures
were body weight, fat mass, hedonic and consummatory eating behaviour during inpatient food challenges, safety and
pharmacokinetics. The primary analysis was the comparison of change scores in the higher-dose treatment group versus placebo
using analysis of covariance at each relevant time point. GSK1521498 (2mg and 5mg) was not different from placebo in its effects
on weight, fat mass and binge eating scores. However, compared with placebo, GSK1521498 5mgday 1 caused a significant
reduction in hedonic responses to sweetened dairy products and reduced calorific intake, particularly of high-fat foods during ad
libitum buffet meals, with some of these effects correlating with systemic exposure of GSK1521498. There were no significant
effects of GSK1521498 2mgday 1 on eating behaviour, indicating dose dependency of pharmacodynamics. GSK1521498 was
generally well tolerated and no previously unidentified safety signals were detected. The potential for these findings to translate
into clinically significant effects in the context of binge eating and weight regain prevention requires further investigation.
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INTRODUCTION
The mu-opioid receptor (MOR), has a critical role in the hedonic
and consummatory aspects of ingestive behaviour.1 In animals,
MOR agonism enhances hedonic reactions to highly palatable
foods and preferentially increases their consumption, whereas
antagonism produces opposite effects.2–9 In humans, MOR
antagonism decreases food palatability and reduces short-term
intake by 11–29%.10
Dysregulation of the MOR system has been implicated in the
pathophysiology of binge eating,11 characterised by recurrent
circumscribed episodes of disproportionate and compulsive food
consumption.12 Binge eating is associated with craving, loss of
control and persistence despite negative consequences and
parallels have been suggested with substance addiction.13 Binge
eating is seen in 23–46% of obese individuals seeking weight loss
treatment14 and its severity relates to body mass index and
predicts regain of lost weight.15–17 However, the relationship is not
deterministic, not all binge eaters become obese and not all obese
individuals binge eat. Nor does this association of binge eating
with obesity define the direction of causality, though studies of
binge-eating disorder15 suggest that binge eating may be a
pathway to obesity.
There is a paucity of pharmacological treatments for binge
eating and/or obesity.11,18 Positive therapeutic effects on both
weight and binge eating have been reported with topiramate
(antiepileptic), atomoxetine (norepinephrine reuptake inhibitor),
sibutramine (mixed monoamine reuptake inhibitor causing
anorexia and thermogenesis), the stimulant phentermine,
selective serotonin reuptake inhibitors and rimonabant
(cannabinoid receptor 1 inverse agonist).19–25 However, safety
concerns regarding psychiatric (rimonabant, topiramate) and
cardiovascular risks (sibutramine, atomoxetine, phentermine)
have hindered the clinical deployment of these treatments [26].
There is a need to explore novel pharmacological approaches,
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guided by the knowledge of the neurochemical systems
implicated in the pathophysiology of abnormal eating. Given the
role of the MOR system in ingestive behaviour and binge eating,
centrally acting mu-opioid antagonists represent a potentially
valuable approach for modulating eating behaviour for the
treatment of obesity.11,16,27–29 Preliminary findings to date using
MOR antagonists for the treatment of obesity and alcohol
dependence have yielded some, though limited, therapeutic
success.11,30
GSK1521498 is a novel opioid antagonist being investigated as
a candidate treatment for behavioural and substance addic-
tions.31–33 It is centrally active and has 14–20-fold greater
selectivity for mu versus kappa and delta opioid receptors.31 In
rodents, GSK1521498 suppressed the intake of standard and
palatable chow and caused weight loss in diet-induced obese
rats.34 It also suppressed food seeking and binge eating showing
superior efficacy to naltrexone.35 In a single dose (25mg) phase 1
study in healthy overweight men, GSK1521498 reduced the
pleasurable response to high-fat and high-sugar food samples and
reduced calorie intake in an ad libitum eating experiment.31 The
current study evaluated the effects of 28 days of GSK1521498
treatment on a range of parameters in binge-eating obese
individuals. We hypothesised that, compared with placebo,
treatment with GSK1521498 would cause significant reductions
in hedonic responses to food and calorific intake, decrease binge-
eating severity and consequently result in weight loss.
SUBJECTS AND METHODS
Participants
Sixty-three volunteers (n¼ 28 (44%) males) aged 18–60 years (mean±s.d.,
41.5±10.0 years) endorsing moderate-to-severe binge eating (Binge-
Eating Scale (BES) scores X19, mean 26.4±6.7)36,37 and with body mass
indexX30 kgm 2 (mean 37.3±4.76 kgm 2) were entered into the study
after signed informed consent. The study (identification number EudraCT
2009-016663-11, ClinicalTrials.gov identifier NCT01195792) was approved
by Berkshire Research Ethics Committee, United Kingdom.
Participants had no history of axis-I disorders (assessed by the Mini-
International Neuropsychiatric Interview) and were excluded if they
reported alcohol intake 414 unitsweek 1, screened positive for illicit
drugs on urine screen, had used nicotine in the past 3 months or taken any
centrally active medications in the preceding 2 weeks. Subjects with Beck
Depression Inventory II Scale total score 413 and/or suicidality
questionnaire score 40 at screening were excluded.38,39
Study design
This was a multi-centre double-blind placebo-controlled parallel group
study. Subjects received 1-week single-blind placebo run-in, followed by
4-weeks treatment with either placebo, GSK1521498 2mgday 1 or
GSK1521498 5mgday 1 capsules (all n¼ 21). Treatment doses were
selected on the basis of a previous positron emission tomography study33
and a 10-day repeat dose study of safety and pharmacokinetics (PK).32 We
predicted that single daily doses of 2mgday 1 and 5mgday 1 would be
well-tolerated with a favourable safety profile and produce average steady
state MOR occupancies of 60.0% and 78.1%, respectively, over 24 h.
The sample size was calculated for the primary endpoint of weight
change of 2.1 kg (s.e. 0.5 kg) from baseline based on a placebo-controlled
study of sibutramine 10mgday 1 for 28 days in obese individuals.40
Assuming a similar magnitude of effect with GSK1521498, it was
determined a priori that the proposed sample size would yield X95%
power to detect this difference with an overall 5% type-I error risk.
Further details of the study design and the CONSORT chart are provided
in the Supplementary Methods.
Procedures and measures
The study flow is summarised in Figure 1. Measures reported herein
constitute a subset of a larger dataset including functional neuroimaging,
some of which will be reported separately (see Supplementary Methods).
Principal assessments and procedures during the study period related to
(i) body weight, fat mass and BES score; (ii) hedonic responses and eating
behaviour during inpatient food challenges; (iii) safety; and (iv) PK. The
designated primary efficacy endpoints were body weight, fat mass and BES
scores.36,37
Aspects of hedonic responses and eating behaviour were examined
during the inpatient visits on Days  1, 14 and 28 using three paradigms:
(i) hedonic taste preference;31,41 (ii) ad libitum snacking;31,41 and (iii)
ad libitum buffet dining. At approximately 1245 hours, subjects were asked
to quantify on a nine-point scale (ranging from ‘dislike extremely’ to ‘like
extremely’), hedonic responses to dairy products of varying fat and sugar
content. This was followed by an ad libitum snack eating challenge41 at
approximately 1330 hours featuring a selection of participants’ favourite
snack foods, categorised into high and low levels of fat and sugar. Total
calorific intake of each food type was recorded.41 These tasks were
previously shown to be sensitive to GSK1521498.31 At pre-specified times
during the day, subjects indicated their preferences for the foods to be
served at the dinner buffet on a menu card. Familiar foods from local
supermarkets, containing 20, 40 or 60% fat were used (no fat content
information was provided) and equicaloric portions of all menu options
were presented at the dinner buffet at approximately 1800 hours.
Additionally, on admission to the unit on days  2, 13 and 27,
participants selected a single main course and dessert from a similar
menu for dinner (‘restaurant meal’). For each subject, all menus were
unique and the total calories consumed and the ranked preference of each
item were recorded.
Safety was assessed serially by means of the Power of Attention (POA)
composite score of drug-induced sedation,32,42 Visual Analogue Scales
(yielding overall subjective scores for alertness, contentedness and
calmness),43–45 clinical instruments (Profile of Mood States—Brief; Beck’s
Anxiety and Depression Inventory; Columbia Suicide Severity Rating Scale;
Young Mania Rating Scale),39,46–49 cardiovascular parameters, adverse
Screening Day-7 Day-1 Day 14 Day 28 Day 35 Day 42
Written informed 
consent, eligibility 
criteria checked
Treatment pack (all 
placebo) for first week. 
Safety assessments. 
Training on tasks
2-3 day inpatient assessments for safety, 
efficacy & pharmacokinetics. Treatment 
packs issued for outpatient days. Principal 
food challenges and computer tasks 
performed at each assessment.
Follow up visits: 
safety and efficacy 
assessments
Single-blind placebo run-in
Double-blind treatment with GSK1521498 
2mg/day, 5mg/day or placebo
Run out
Inpatient assessment
Figure 1. Schematic representation of the study schedule.
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events and standard laboratory measures (urea, electrolytes, liver function
tests, full blood count). Other aspects of hedonic function were assessed
using self report (Temporal Experience of Pleasure; Changes in Sexual
Functioning Questionnaire-1450,51).
For the estimation of PK parameters, plasma concentrations of
GSK1521498 were sampled serially on days 1 and 28. Pre-dose samples
were collected on days 7, 14 and 21 for the estimation of steady state
(trough) concentrations.
Some participants provided additional consent for pharmacogenetic
analysis of a venous blood sample. Previous studies have implicated the
A118G single nucleotide polymorphism of the OPRM1 gene in variability of
therapeutic response to naltrexone and other MOR antagonists.52,53 We
therefore genotyped all consenting Caucasian participants at this allele
(see Supplementary Material for details).
Statistical analyses
The primary analyses focused on change scores for each endpoint at each
time point in the higher dosing cohort (GSK1521498 5mgday 1) versus
placebo. Change scores for each endpoint were calculated by subtracting
the baseline values from the post-randomisation values for each subject at
each time point; missing data were not replaced. Repeated measures of
analysis of covariance models with PROC MIXED from SAS were used,
fitting gender, treatment, day and study day-by-treatment interaction as
fixed effects and baseline score as a covariate.
For inpatient food challenges, measures were analysed hierarchically:
first, overall hedonic ratings during taste testing and total calorific intake
during ad libitum snacking and ad libitum buffet dining were analysed.
Where global measures were statistically significant for a given paradigm,
supplementary analyses were conducted for the high-fat/high-sugar
conditions; and where significant, for low-fat/low-sugar conditions to
assess specificity of drug effects.
If significant treatment effects were identified in the GSK1521498
5mgday 1 group versus placebo, possible dose dependency was
evaluated in two ways: firstly, we conducted supplemental analyses in
the GSK1521498 2mgday 1 group; and secondly, we estimated correla-
tions between trough GSK1521498 plasma concentrations and pharma-
codynamic endpoints measured over all study participants. This approach
minimised the number of statistical comparisons, as the most pronounced
effects of treatment were expected a priori for the higher dose, but also
permitted dose dependency to be evaluated comprehensively.
This being an exploratory study in which the interest lay equally in
determining ‘an effect’ versus ‘no effect’ of active treatment compared
with placebo, statistical significance was defined as two-tailed Po0.05
uncorrected, and the sample size was powered to justify this (vide supra).
RESULTS
Demographic characteristics for all subjects are displayed in
Table 1. There were no significant differences between the groups
on baseline measures of age, gender balance, weight, body mass
index or total BES score (all P40.10).
Pharmacokinetics
Both 2mg and 5mg doses were absorbed rapidly with a median
time to maximal concentration (Tmax) of 2–3 h on Days 1 and 28.
Consistent with the previously reported half-life of 20–24 h,31
approximate steady state levels were achieved by Day 7 (see
Supplementary Figure S2 and Supplementary Table S4). Estimated
mean MOR occupancy based on the steady state levels ranged
between 64 and 80% for a 2-mg dose and 82–92% for a 5-mg
dose.
Primary efficacy measures
Figure 2, top panel indicates the mean body weight, fat mass and
BES scores for the three treatment arms over time. Body weight
and fat mass were relatively stable in all the groups, while BES
scores reduced over time in all the groups both before and after
randomisation. Analysis of covariance indicated no differential
effects of 5mgday 1 GSK1521498 on the primary efficacy
measures compared with placebo (all P40.10). However, a
significant correlation was seen between the changes in the BES
score and weight (in the 5mg group, Pearson’s r¼ 0.719,
P¼ 0.0004; across all subjects r¼ 0.4, P¼ 0.0018), that is, greater
reduction of binge eating was associated with greater weight loss.
Moreover, the small sub-group of participants (N¼ 3) with one or
more copies of the 118G allele (‘G-carriers’) demonstrated greater
weight reduction (t(df)¼  4.41(28), P¼ 0.0001; see Figure 3,
Supplementary Table S3) compared with A118 homozygotes
(N¼ 12).
Hedonic responses and eating behaviour
Hedonic responses. Treatment with GSK1521498 5mgday 1
significantly reduced hedonic ratings for sweetened dairy
products overall, on Day 14 (t(df)¼ 2.36(59), P¼ 0.0215) and Day
28 (t(df)¼ 2.61(57), P¼ 0.0115), compared with placebo (Figure 2,
middle panel). Follow-up analyses indicated that this was due to
Table 1. Baseline characteristics and demographics
Run-in only Placebo 498 2mg 498 5mg Total
Number of subjects
Planned, N 0 20 20 20 60
Dosed, N 4 21 21 21 67
Completed, n (%) 0 21 (100) 18 (86) 21 (100) 60 (90)
Total number of subjects withdrawn, n (%) 4 (100) 0 3 (14) 0 7 (10)
Withdrawn due to adverse event, n (%) 1 (25) 0 2 (10)a 0 3 (4)a
Withdrawn at investigator discretion, n (%) 2 (50) 0 1 (5) 0 3 (4)
Subject withdrew consent, n (%) 1 (25) 0 0 0 1 (1)
Demographics
N (all subjects) 4 21 21 21 67
Mean age in years (s.d.) 44.8 (9.50) 41.3 (9.22) 44.9 (10.08) 37.8 (10.06) 41.5 (10.00)
Females: males 2:2 11:10 12:9 12:9 37:30
Mean Weight in kg (s.d.) 109.7 (21.68) 109.2 (18.17) 110.9 (23.63) 104.0 (9.82) 108.1 (18.11)
Mean body mass index in kgm 2 (s.d.) 36.2 (4.15) 37.8 (4.87) 37.1 (5.37) 37.1 (4.38) 37.3 (4.76)
White/Caucasian/European heritage, n (%) 4 (100) 17 (81) 19 (90) 17 (81) 57 (85)
African American/African heritage, n (%) 0 3 (14) 2 (10) 3 (14) 8 (12)
White—Arabic/North African heritage, n (%) 0 1 (5) 0 1 (5) 2 (3)
aIncludes one subject withdrawn from the study due to a serious adverse event.
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significant effects on pleasurable response to high-sugar (Day 14:
t(df)¼ 3.14(141), P¼ 0.0021; Day 28: t(df)¼ 3.09(141), P¼ 0.0024)
and high-fat food samples (Day 14: t(df)¼ 2.01(132), P¼ 0.0464;
Day 28: t(df)¼ 2.45(132), P¼ 0.0157), with no effects on responses
to low-fat and low-sugar samples (all P40.10; Figure 2, bottom
panel). No significant effect of GSK1521498 2mgday 1 on overall
hedonic preference was detected for Day 14 or 28 (both P40.10).
No gender effects were seen. The changes in overall, high-fat and
high-sugar hedonic responses were negatively correlated with the
maximal plasma drug concentration (Cmax) (r¼  0.33, P¼ 0.01;
r¼  0.353, P¼ 0.0055; r¼  0.34, P¼ 0.007) and 24-h drug
exposure (AUC24) (r¼  0.31, P¼ 0.017; r¼  0.34, P¼ 0.0094;
r¼  0.33, P¼ 0.011). (see Supplementary Figure S4).
Ad libitum snacking. There was a non-significant trend towards
reduction in overall calorific intake in the GSK1521498 5mgday 1
group compared with placebo on Day 14 (t(df)¼ 1.73(58),
P¼ 0.0883) but not on Day 28 (P40.10).
Ad libitum buffet dining. There was a significant reduction in total
calorific intake in the GSK1521498 5mgday 1 group versus
placebo, on Day 14 (t(df)¼ 2.10(52), P¼ 0.0405) and Day 28
(t(df)¼  2.74(45), P¼ 0.0087; Figure 2, middle panel). Follow-up
analyses for Day 28 indicated that this finding was largely
attributable to a significant reduction in calorific intake for the
main courses (21.4%, t(df)¼  2.4(45), P¼ 0.0207) and the 60% fat
dessert (24.75%, t(df)¼ 2.35(48), P¼ 0.023; Figure 2, bottom
panel). Men consumed more calories than women; but there
was no drug-by-gender interaction. There was no significant effect
in the 2mgday 1 GSK1521498 group versus placebo (P40.10).
Variation in the main course calorie intake was negatively
correlated with Cmax (Pearson’s r¼  0.29, P¼ 0.036). The changes
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in hedonic responses did not correlate with changes in calorie
intake (Supplementary Table S11).
There was no significant change in intake at the restaurant
meals in the GSK1521498 5 mgday 1 group (P40.10) and no
change in the ranked preferences on the menus on either the
buffet or the restaurant meals (Supplementary Results).
Safety results
Power of attention. There was no significant effect of GSK1521498
5mgday 1 on the POA composite score of drug-related sedation on
Days  1 and 28 (all P40.10; Supplementary Table S15).
Visual analogue scales. There were statistically significant impair-
ments in alertness, contentedness and calmness scores in the
GSK1521498 5mgday 1 group compared with placebo on Day 1
only (t(df)¼ 2.89(57), P¼ 0.005; t(df)¼ 2.77(57), P¼ 0.008; and
t(df)¼ 2.30(57), P¼ 0.0253, respectively; Figure 4, Supplementary
Table S15). These three measures increased from baseline by
19–34% in the placebo group between Day  1 and Day 1 as
compared with relatively static levels (changes of  1% to þ 6%)
seen in the active treatment group.
Exploration of dose dependency revealed a trend towards a
reduction on calmness alone (t(df)¼ 1.74(58), P¼ 0.087; other
P40.10) with GSK1521498 2mgday 1 compared with placebo.
No significant gender differences or correlations with PK
parameters were seen.
Clinical safety instruments. There were no significant or trend
significant effects of GSK1521498 (2mg or 5mg) compared with
placebo on the Profile of Mood States—Brief, Beck’s Anxiety and
Depression Inventory (all P40.10; Supplementary Table S15). No
subjects endorsed suicidality on the Columbia Suicide Severity
Rating Scale and only one subject reported a non-zero Young
Mania Rating Scale score (not clinically significant). No significant
treatment differences were observed for GSK1521498 versus
placebo for change from baseline in Temporal Experience of
Pleasure or Changes in Sexual Functioning Questionnaire-14
scores (Supplementary Tables S20 and S21).
Cardiovascular parameters. There was no significant effect of
GSK1521498 at either dose on pulse or blood pressure versus
placebo (all P40.05, Supplementary Figure S5). No abnormal or
clinically significant electrocardiogram findings were detected.
Adverse events. The proportion of subjects reporting any adverse
event was similar in all the three treatment groups: 86, 81 and
76% for GSK1521498 2mgday 1, GSK1521498 5mgday 1 and
placebo, respectively (chi-square, P40.10), and the majority were
of mild-to-moderate severity (Supplementary Table S17). The
incidence of commonly reported adverse events was similar
across the treatment groups; some gastrointestinal effects (for
example, diarrhoea, abdominal discomfort) tended to be more
commonly reported in the GSK1521498 groups. Three subjects
were withdrawn from the GSK1521498 2mgday 1 cohort for
reasons deemed by the investigator to be unrelated to the study
-3
-2
-1
0
1
2
Mean weight change by genotype
W
ei
gh
t c
ha
ng
e 
fro
m
 b
as
el
in
e(k
g)
DAY -1 DAY 14 DAY 28
AA
AG
***
W
ei
gh
t c
ha
ng
e 
fro
m
 b
as
el
in
e 
(kg
)
-3
-2
-1
0
1
2
Weight change for all subjects
DAY -1 DAY 14 DAY 28
AA
AG
Figure 3. Pharmacogenetic analyses: three subjects in the GSK1521498 5mgday 1 group with one or more copies of the 118 G allele (AG)
were compared with A118 homozygotes (AA, N¼ 12). The left panel depicts the mean weight change over the treatment period and the right
panel displays the individual weight plots for all 15 Caucasian subjects. It can be seen that greatest weight change is seen in two of the
G-carriers (AG). ***Po0.001.
Sc
re
en
in
g
D
ay
 -7
D
ay
 -1
D
ay
 1
D
ay
 2
D
ay
 7
D
ay
 1
4
D
ay
 2
1
D
ay
 2
8
D
ay
 
35
, f
ol
lo
w-
u
p
D
ay
 
42
, f
ol
lo
w-
u
p
Co
nt
en
te
dn
es
s,
 m
m
 [S
EM
]
40
50
60
70
80
90
100
Al
er
tn
es
s,
 m
m
 [S
EM
]
40
50
60
70
80
90
100
Placebo 
5mg/day GSK498
Sc
re
e
n
in
g
D
ay
 -7
D
ay
 -1
D
ay
 1
D
ay
 2
D
ay
 7
D
ay
 1
4
D
ay
 2
1
D
ay
 2
8
D
ay
 3
5,
 fo
llo
w-
u
p
D
ay
 4
2,
 fo
llo
w-
u
p
Ca
lm
ne
ss
, m
m
 [S
EM
]
40
50
60
70
80
90
100
Time point Time point Time point
*
*
*
Sc
re
en
in
g
D
ay
 -7
D
ay
 -1
D
ay
 1
D
ay
 2
D
ay
 7
D
ay
 1
4
D
ay
 2
1
D
ay
 2
8
D
ay
 3
5,
 fo
llo
w-
u
p
D
ay
 4
2,
 fo
llo
w-
u
p
Figure 4. Changes in Visual Analogue Scale measures of alertness, calmness and contentedness in the placebo and GSK1521498 groups over
the study duration. *Po0.05.
Novel opioid antagonist effects on eating behaviour
H Ziauddeen et al
1291
& 2013 Macmillan Publishers Limited Molecular Psychiatry (2013), 1287 – 1293
drug: one due to arthralgia; one became pregnant; and one
subject reported persecutory delusions following randomisation.
Clinical interview by a consultant psychiatrist (EB), who also
obtained collateral history from this subject’s parents, suggested
long-standing delusions, the nature and intensity of which were
unrelated to study participation or receiving active treatment. This
subject was referred for urgent local mental health follow-up.
Safety laboratory measures. There were no significant effects of
treatment with GSK1521498 on any of the primary safety
laboratory parameters (see Supplementary Figure S6).
DISCUSSION
This study assessed the effects of 4-weeks of treatment with the
MOR antagonist GSK1521498 on hedonic evaluation and con-
sumption of food, binge-eating severity and body weight in obese
people with binge-eating symptoms. There were two key effects:
GSK1521498 was associated with significant reductions in hedonic
preference, specifically for higher concentrations of sugar and fat.
GSK1521498 also markedly reduced calorie intake in an ad libitum
buffet and particularly for more palatable foods (high-fat desserts).
These effects were dose dependent, occurring only in the 5mg
group, and were, to an extent, correlated with variability in plasma
concentrations of GSK1521498. These observations are in keeping
with predictions and offer proof of the drug’s mechanistic on-
target effects.
The effects of GSK1521498 were not entirely consistent across
all measures of eating behaviour. Changes in hedonic ratings did
not correlate with the effects on calorie intake, perhaps because
the latter involved multiple foods of varying compositions,
whereas the former used relatively homogeneous food samples.
No significant effects on consumption were found for the ad
libitum snacking or the restaurant meal. The snacking paradigm
may quantify a type of eating that is relatively difficult to modify:
consumption of favourite foodstuffs following prolonged fasting
(412 h). The restaurant meal captures consumption in a context
with limited food availability. It appears that the effects of mu-
opioid antagonism become apparent only in settings that permit
overconsumption. This distinction might be considered akin to
eating what is in the fridge rather than eating what is on the plate.
Moreover, these effects on eating behaviour measured by in-
unit assessments did not translate into reductions in weight or fat
mass. There are several possible reasons for this. First, acute
changes in hedonic and consummatory aspects of eating may
take longer than 28 days to translate to changes in habitual
decision making about food consumption, sufficient to cause
significant weight loss. The duration of this study was limited by
the toxicological data currently available for GSK1521498. Second,
participants were treated as outpatients without dietary restriction
or other active lifestyle management interventions. It is a
limitation of the design that we do not have data on calorie
consumption outside the controlled setting of in-unit assess-
ments. Third, there may be significant heterogeneity between
obese patients in their responsiveness to GSK1521498 or other
MOR antagonists. For example, post-hoc pharmacogenetic analy-
sis showed that a small sub-group of Caucasian participants
carrying one or more copies of the 118G allele of the OPRM1 gene
in the 5mg treatment group showed a greater weight reduction
compared with A118 homozygotes: indeed two of the three
subjects who showed the greatest weight loss were G-carriers.
These data must be treated with caution given the post-hoc,
exploratory nature of the analysis and the very small sample size.
Nonetheless, they suggest that allelic variation in the MOR gene
may contribute to variable therapeutic response to MOR
antagonists in the treatment of obesity. Finally, we note that the
highest dose of GSK1521498 administered was not sufficient to
cause sustained receptor occupancy 490% and high levels of
MOR blockade have been considered necessary for optimal thera-
peutic effect of naltrexone and other MOR antagonists.54 The
encouraging safety profile of GSK1521498 suggests that repeated
dosing up to 10mgday 1 may be tolerable in outpatients and
higher doses might be expected to demonstrate stronger
therapeutic effects in future studies of obesity.
Certain other limitations should be considered. BES scores
diminished considerably across all groups even before randomisa-
tion, limiting the ability to discriminate any benefits of active
treatment on this endpoint. The use of the self-reported BES is a
limitation as high placebo response rates have been reported with
subjective measures in clinical trials in binge-eating individuals.27
The findings are preliminary as the study was not powered to
correct for multiple comparisons; however, we did deploy
strategies designed to minimise these.
Multiple anti-obesity agents have been withdrawn due
to central/psychiatric/cardiovascular safety concerns.26,55,56
GSK1521498 was generally well tolerated compared with
placebo, with no deleterious effects detected on anxiety, mood
or other aspects of hedonic function or on liver or other blood
safety parameters. Akin to previous studies,31,32 transient
impairments on subjective ratings of alertness, contentedness
and calmness, were seen with GSK1521498 on the first day of
active treatment, largely driven by relative increases in the
placebo group. Therefore, the only central effects of
GSK1521498 identified were mild and not clinically significant.
Although the lack of effect on weight does not support immediate
progression for obesity therapeutics, the effects on eating behaviour
and the early pharmacogenetic data warrant further evaluation of
GSK1521498 as a more genetically targeted treatment in obesity and
binge eating. The similarities between the MOR dysregulation in
binge eating and substance addiction motivate exploration of
GSK1521498 as a treatment for drug addictions. This study highlights
the value of using experimental medicine models to demonstrate
clinical proof-of-mechanism for a novel compound targeting
abnormal reward-driven eating behaviour.
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